利妥昔单抗治疗AChR阳性重症肌无力的疗效持久性
该回顾性病例系列纳入16例AChR阳性全身型重症肌无力患者,接受利妥昔单抗治疗后随访18至84个月。所有患者均达到完全稳定缓解、药物缓解或轻微表现,9例(56%)复发,7例(44%)无复发;抗AChR抗体水平随治疗周期逐步下降。
要点
- 利妥昔单抗可使难治性AChR阳性重症肌无力患者获得持久缓解。
- 约56%患者在中位随访36个月时复发,需关注复发标志物。
- 抗AChR抗体水平随利妥昔单抗周期逐步下降,但血清细胞因子未变。
核心结论
- 利妥昔单抗对难治性AChR阳性全身型重症肌无力有效,且部分患者缓解持久。
研究设计与样本
- 患者接受利妥昔单抗治疗,治疗后随访18至84个月。
主要发现
- 16例患者(6男10女;中位年龄42岁,范围18-69岁)中,所有患者达到完全稳定缓解、药物缓解或轻微表现。
- 9例(56%)在平均随访36个月(范围24-47个月)内复发,7例(44%)在平均随访47个月(范围18-81个月)内无复发。
- 血清细胞因子水平未发现变化。
关键数值与推荐
- 临床改善与完全停用或减少其他免疫治疗同步,所有患者达到MGFA干预后状态标准的完全稳定缓解、药物缓解或轻微表现。
临床怎么用
- 利妥昔单抗可作为难治性AChR阳性全身型MG的治疗选择,但需监测复发。
- 抗AChR抗体水平可随利妥昔单抗周期下降,但细胞因子水平未变,其临床意义待明确。
局限性
- 回顾性病例系列设计,样本量小(16例),无对照组,结论需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Myasthenia gravis (MG), an autoimmune disorder of neuromuscular transmission, is treated by an array of immunotherapeutics, many of which are nonspecific. Even with current therapies, a subset of patients has medically refractory MG. The benefits of B-cell-targeted therapy with rituximab have been observed in MG; however, the duration of these benefits after treatment is unclear. OBJECTIVE: To evaluate the durability of response to rituximab in the treatment of acetylcholine receptor autoantibody-positive (AChR+) generalized MG. DESIGN, SETTING AND PARTICIPANTS: This retrospective case series study included 16 patients with AChR+ MG referred to an MG clinic from January 1, 2007, to December 31, 2015. The patients were treated with rituximab and followed up for 18 to 84 months after treatment. MAIN OUTCOMES AND MEASURES: Assessment of long-term clinical response, durability of response and/or relapse rate, AChR autoantibody levels, adverse effects, and inflammatory markers. RESULTS: In the 16 patients (6 men and 10 women; median age, 42 [range, 18-69] years), clinical improvement was observed in parallel with complete withdrawal or reduction of other immunotherapies, with all patients achieving complete stable remission, pharmacologic remission, or minimal manifestations based on the Myasthenia Gravis Foundation of America postintervention status criteria. Nine patients (56%) had a relapse during a mean follow-up of 36 (range, 24-47) months. Seven patients (44%) remained relapse free with a mean follow-up of 47 (range, 18-81) months since the last rituximab treatment. All values were normalized to a pretreatment anti-AChR antibody level of 100% and the mean levels after each rituximab cycle were calculated. A 33% decrease was seen after cycle 1 of rituximab treatment (100% vs 67%; P = .004); 20% after cycle 2 (compared with cycle 1) (67% vs 47%; P = .008); and 17% after cycle 3 (compared with cycle 2) (47% vs 30%; P = .02). However, the serum cytokine levels measured were found to be unchanged. CONCLUSIONS AND RELEVANCE: Rituximab therapy appears to be an effective option in patients with refractory AChR+ MG, who were observed to have a durable response after treatment. Identification of markers of disease relapse and sustained remission are critical next steps in the development of pathophysiology-relevant, evidence-based practice parameters for rituximab in the treatment of MG.
引用
- Robeson KR, Kumar A, Keung B, et al. Durability of the Rituximab Response in Acetylcholine Receptor Autoantibody-Positive Myasthenia Gravis. JAMA Neurol. 2017. PMID: 27893014. doi:10.1001/jamaneurol.2016.4190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。